Join the 20:20 Challenge for GIST Cancer UK!

We have joined forces with 19 other less common cancer charities to create a unique & exciting 20-day challenge called the 20for20 Challenge to raise funds to make up the shortfall in our income due to the pandemic. Funds that are vital to enable us to continue with our work. The Covid-19 pandemic has led […]

Continue reading

GCUK PAWS-GIST funded research published in The Journal of Clinical Pathology

In 2017 GIST Cancer UK approved a research grant application for pathologist Dr Newton Wong to undertake next generation sequencing  (NGS) of wild-type GIST’s to identify therapeutic targets. Earlier this month (July 2020) – Dr Wong’s research paper “Next generation sequencing demonstrates the rarity of short kinase variants specific to quadruple wild type gastrointestinal stromal […]

Continue reading

New cancer drug Entrectinib (Rozlytrek) approved for Cancer Drug Fund in England

We are very pleased to hear that NICE has approved the Roche drug Entrectinib (Rozlytrek), for use via the Cancer drug fund (CDF) in England by adults and children 12 years and older, who have advanced NTRK (Neurotrophic Tyrosine Receptor Kinase) fusion-positive solid tumours and no satisfactory treatment options. Eligible patients will have access to […]

Continue reading

VOYAGER Phase 3 clinical trial results…

This week Blueprint Pharmaceuticals announced the results of their Voyager trial which compared AYVAKIT™ (avapritinib) with Regorafenib. The trial did not meet the main aim (or endpoint). As a result they are proposing: To continue promoting avapritinib in the United States for the treatment of adults with unresectable or metastatic PDGFRA exon 18 mutated GIST, including […]

Continue reading

New Cancer drug Larotrectinib (Vitrakvi) approved for Cancer Drug Fund in England

We are very pleased to announce that NICE has approved the Bayer drug Larotrectinib (Vitrakvi) for use via the Cancer drug fund (CDF) in England for adults and children who have failed other treatment options and whose tumours test positively for the rare NTRK fusion (Neurotrophic Tyrosine Receptor Kinase fusion). Described as an histology agnostic […]

Continue reading